Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: All

Summary

An open-label, multicentre study to evaluate the efficacy and safety of one course of weekly intramuscular administration of Amevive in Taiwan patients with chronic plaque psoriasis

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Uni-Pharma
• Collaborator: Biogen
• Treatments: Alefacept

Criteria

Inclusion Criteria:

• Must give written informed consent

• Must be >= 16 years of age

• Must have been diagnosed with chronic plaque psoriasis at least one year and require systemic or phototherapy

• Must have CD4+ lymphocyte count at or above the lower limit of normal

• Must have a BSA >= 10%

Exclusion Criteria:

• Current erythrodermic, generalized pustular, or guttate psoriasis

• Serious local infection or systemic infection within 3 months prior to the first dose of alefacept

• History of any clinical significant disease that would be contraindicated for this study as determined by the investigator

• Prior history of systemic malignancy, untreated localised skin canceer or a >10 squamous cell carcinoma

• Current enrollment in any other investigational drug study within 30 days prior to study drug administration

• Treatment with systemic immunosuppressant agents within the 4 weeks prior to study drug administration.